Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO).

J Immunother Cancer · 2022 · PMC9594538 · PMID 36270733

Europe PMC DOI

hedged sentence

0.2100

closest p · 4.2× alpha

0.2100

boldest claim

The sentences

a positive trendp=0.21not close (p > 0.1)

A positive trend between MPR and OS was also observed (n=43, log-rank test p=0.21): all 8 patients with MPR were alive (12-month OS: 100%) vs 31/35 patients with >10% residual tumor cells (12-month OS: 89%, 95% CI 72.4% to 95.6%) ( figure 2C, D ).

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.